Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study
| Autor: | Deborah I. Ritter, Ata S. Moshiri, Mark H. Wener, Masaoki Kawasumi, Jayasri G. Iyer, Aaron Lisberg, Erica S. Tarabadkar, William T. Simonson, Lola Mudgistratova, C. Lewis, Chihiro Morishima, Joseph J. Carter, Kelly G. Paulson, Astrid Blom, Paul Nghiem, Denise A. Galloway, Kathleen Hutchinson, Shailender Bhatia, Mary W. Redman |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Merkel cell polyomavirus Lower risk 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Prospective cohort study biology business.industry Merkel cell carcinoma Antibody titer food and beverages biology.organism_classification medicine.disease Titer 030104 developmental biology 030220 oncology & carcinogenesis Immunology Cohort Skin cancer business |
| Zdroj: | Cancer. 123:1464-1474 |
| ISSN: | 0008-543X |
| DOI: | 10.1002/cncr.30475 |
| Popis: | BACKGROUND Merkel cell carcinoma (MCC) is an aggressive skin cancer with a recurrence rate of >40%. Of the 2000 MCC cases per year in the United States, most are caused by the Merkel cell polyomavirus (MCPyV). Antibodies to MCPyV oncoprotein (T-antigens) have been correlated with MCC tumor burden. The present study assesses the clinical utility of MCPyV-oncoprotein antibody titers for MCC prognostication and surveillance. METHODS MCPyV-oncoprotein antibody detection was optimized in a clinical laboratory. A cohort of 219 patients with newly diagnosed MCC were followed prospectively (median follow-up, 1.9 years). Among the seropositive patients, antibody titer and disease status were serially tracked. RESULTS Antibodies to MCPyV oncoproteins were rare among healthy individuals (1%) but were present in most patients with MCC (114 of 219 patients [52%]; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text